Yu et al. (2026)
- Authors: Qiang Yu, Kiana Kothe, Richard A. Kwiatek, Peter Del Fante, Anya Bonner, Vince D. Calhoun, Zuyao Y. Shan
- Institutes: Sunshine Coast Mind and Neuroscience – Thompson Institute, University of the Sunshine Coast, Birtinya, Queensland, Australia, Tri-institutional Center for Translational Research in Neuroimaging and Data Science (TReAD), Georgia State University, Atlanta, GA, USA, University of Adelaide, Adelaide, South Australia, Australia
- Publisher: Human Brain Mapping (Wiley)
- Link: DOI
Summary
This research provides objective evidence that ME/CFS involves measurable inflammation within the brain’s white matter, validating the biological nature of the disease. By utilizing advanced imaging, researchers identified specific signs of edema and cellular changes that are invisible to standard MRI scans. These findings help explain why patients often have ‘normal’ results despite severe symptoms. The correlation between these brain changes and clinical disability levels suggests these imaging markers could serve as much-needed diagnostic biomarkers. This discovery moves the field closer to targeted therapies designed to address neuroinflammation directly.
What was researched?
This study investigated the presence of white matter neuroinflammation in ME/CFS using an advanced Neuroinflammation Imaging (NII) model. The researchers aimed to identify specific microstructural brain changes that correlate with clinical symptoms and disease severity.
Why was it researched?
ME/CFS has long been suspected to involve neuroinflammation, but conventional MRI techniques like Diffusion Tensor Imaging (DTI) have provided inconsistent and poorly characterized results. Advanced imaging models were required to detect subtle inflammatory signatures such as edema and cellular infiltration in vivo.
How was it researched?
Researchers analyzed diffusion MRI data from 67 ME/CFS patients and 67 age- and gender-matched healthy controls. They calculated seven NII-derived metrics—including hindered water ratio and restricted fraction—to assess brain abnormalities and compared these results with conventional DTI metrics. Multiple regression analysis was used to examine the relationship between these brain imaging markers and clinical measures of mental health, sleep quality, disability, and disease duration.
What has been found?
Patients with ME/CFS exhibited widespread white matter abnormalities characterized by signs of cerebral edema, cellular changes, and axonal reorganization. Specifically, lower levels of certain NII markers were significantly associated with worse mental health and increased levels of disability. In contrast, conventional DTI failed to show significant differences between the groups or meaningful clinical associations. Higher fiber fraction was notably associated with lower disease severity in the patient group.
Discussion
The findings suggest that NII-derived metrics are far more sensitive than traditional imaging methods for detecting the neuroinflammatory pathophysiology of ME/CFS. A key strength of the study is the use of a rigorously matched cohort and the identification of associations between imaging markers and functional disability. The research highlights the potential for these specific white matter changes to explain the diverse symptom profile of the disorder.
Conclusion & Future Work
The study concludes that white matter neuroinflammation is a hallmark of ME/CFS pathophysiology. These advanced imaging indices provide sensitive biomarkers that could aid in diagnosis and treatment monitoring. Future research is encouraged to validate these markers in larger, longitudinal trials.